The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to izalontamab brengitecan (iza-bren), an […]
Category: News
Merck’s therapy becomes first authorised option for aggressive soft tissue tumours
Project aims to improve global immunisation through needle-free delivery
Company shifts focus to phase 3 VE303 trial in recurrent C. difficile infection
Lilly’s study finds tirzepatide delivers broader health improvements
Teva’s CGRP therapy becomes first approved option for children and adolescent
Promising results support global submissions and priority review by US FDA
Pirtobrutinib meets primary endpoint in CLL/SLL study
Nationwide competition to pilot new models of obesity support
New phase of development targets chronic pain and fibromyalgia